Results 51 to 60 of about 6,394 (171)

Burden of diabetic macular oedema and its associated factors among adult patients with diabetes attending comprehensive specialised hospitals in Northwest Ethiopia, 2023: a multicentre cross-sectional study

BMJ Open
Objective This study aimed to assess the prevalence of diabetic macular oedema and its associated factors among adult patients with diabetes attending comprehensive specialised hospitals in Northwest Ethiopia in 2023.Design An institution-based, cross ...
Biruk Lelisa Eticha, Matiyas Mamo Bekele, Abebech Fikade Shumye, Mebratu Mulusew Tegegne, Asamere Tsegaw Woredekal   +4 more
doaj   +1 more source

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema [PDF]

, 2018
Purpose To evaluate changes in colour vision following intravitreal injection of Dexamethasone implant (Ozurdex) in patients with diabetic macular oedema (DMO).
Abdel-hay, A., Barbur, J. L., Sivaprasad, S., Subramanian, A.   +3 more
core   +2 more sources

Pseudophakic cystoid macular edema: update 2016 [PDF]

, 2016
Pseudophakic cystoid macular edema (PCME) is the most common complication of cataract surgery, leading in some cases to a decrease in vision. Although the pathogenesis of PCME is not completely understood, the contribution of postsurgical inflammation is
Ascaso, Francisco J., Grzybowski, Andrzej, Huerva, Valentín, Sikorski, Bartosz L   +3 more
core   +4 more sources

Aflibercept for the therapy of retinal diseases. A review of clinical studies

Российский офтальмологический журнал, 2018
Aflibercept is a hybrid protein-imitation of VEGF receptor with a prolonged activity. The review describes the structural properties of the Aflibercept molecule, the impact of the medication on the pathogenesis of retinal diseases, and the results of ...
T. D. Okhotsimskaya, O. V. Zaitseva
doaj   +1 more source

Review of Diabetic Macular Oedema Therapy [PDF]

European Ophthalmic Review, 2017
Within the realm of diabetic retinopathy, diabetic macular oedema (DMO) is one of the most common causes of visual loss in the young adult population. In this review, we will discuss the epidemiology, pathophysiology and treatment of DMO. A brief historical view of the treatment perspective will be presented as well.
Kevin J Blinder, R Maria Peralta
openaire   +1 more source

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Optical coherence tomography (OCT)‐derived retina measurements are markers for neuroaxonal visual pathway status. High‐quality OCT scans are essential for reliable measurements, but their acquisition is particularly challenging in eyes with severe visual impairment, as often observed in neuromyelitis optica spectrum disorders ...
Hadi Salih, Sara Samadzadeh, Charlotte Bereuter, Seyedamirhosein Motamedi, Claudia Chien, Pablo Villoslada, Hadas Stiebel‐Kalish, Nasrin Asgari, Yang Mao‐Draayer, Marius Ringelstein, Joachim Havla, Marco Aurélio Lana Peixoto, Ho Jin Kim, Jacqueline Palace, Maria Isabel Leite, Srilakshmi M. Sharma, Fereshteh Ashtari, Rahele Kafieh, Lekha Pandit, Orhan Aktas, Philipp Albrecht, Letizia Leocani, Itay Lotan, Sasitorn Siritho, Jérôme de Seze, Romain Marignier, Caroline Froment Tilikete, Denis Bernardi Bichuetti, Ivan Maynart Tavares, Ayse Altintas, Anu Jacob, Saif Huda, Ibis Soto de Castillo, Lawrence J. Cook, Michael R. Yeaman, Axel Petzold, Alexander U. Brandt, Friedemann Paul, Frederike C. Oertel, Hanna G. Zimmermann, with the Guthy Jackson Charitable Foundation—International Clinical Consortium and CROCTINO Collaborators   +40 more
wiley   +1 more source

Influence of glycaemic control on macular thickness in diabetic retinopathy

Endocrinology, Diabetes & Metabolism, 2022
Introduction Diabetic macular oedema (DME) is one of the major cause of decreased visual acuity in patients with diabetic retinopathy. Poor glycaemic control is associated with increased incidence of DME.
Sadhana Sharma, Pratap Karki, Sagun Narayan Joshi, Sanket Parajuli   +3 more
doaj   +1 more source

The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema [PDF]

, 2016
Aims: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database.
Akerele, T., Bailey, C., Brand, C., Chakravarthy, U., Crabb, D. P., Denniston, A., Downey, L., Egan, C., Fitt, A., Johnston, R., Khan, R., Kumar, V., Lee, A., Lobo, A., Mahmood, S., Mandal, K., McKibbin, M., Menon, G., Mitry, D., Natha, S., Sim, D., Tsaloumas, M., Tufail, A., Varma, A., Wilkinson, E., Zhu, H.   +25 more
core   +1 more source

Navigated Laser Therapy for Diabetic Macular Oedema [PDF]

European Ophthalmic Review, 2010
Navigated laser therapy introduces computerised assistance systems to retinal laser photocoagulation treatment. As main benefits over conventional laser, the Navilas system offers high precision and safety and provides additional advantages regarding standardisation of planning, execution, documentation, quality assurance and better overall treatment ...
Marcus, Kernt, Michael, Ulbig, Anselm, Kampik, Aljoscha S, Neubauer   +3 more
openaire   +2 more sources

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source